deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04030195

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Sponsor: Precision BioSciences, Inc.

Conditions B-cell Chronic Lymphocytic Leukemia B-cell Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Chronic Lymphoid Leukemia in Relapse Leukemia, Lymphocytic, Chronic Lymphoma, Non-Hodgkin Non-Hodgkin's Lymphoma Refractory Non-Hodgkin's Lymphoma, Relapsed Small Lymphocytic Lymphoma
Interventions Cyclophosphamide Fludarabine PBCAR20A
Updated 13 times since 2019 Last updated: Jan 4, 2023 Started: Mar 24, 2020 Primary completion: Jun 24, 2021 Completion: Jun 24, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on B-cell Chronic Lymphocytic Leukemia and B-cell Non Hodgkin Lymphoma, this trial is completed. The trial is conducted by Precision BioSciences, Inc. and has accumulated 13 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2019 – ~Apr 2020 · 8 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jul 2022 · 14 months · monthly snapshot~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jul 2022 — Feb 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. May 2021 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Aug 2019 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Precision BioSciences, Inc.
Data source: Precision BioSciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations